

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-113 (Cancelled)

114. (New) An isolated polypeptide comprising:
- a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
wherein said sequence comprises a K179E SNP.
115. (New) A composition comprising the polypeptide of claim 114 and at least one excipient.
116. (New) The composition of claim 115, wherein said excipient is a pharmaceutically acceptable excipient.
117. (New) The composition of 115, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
118. (New) A pharmaceutical composition comprising the polypeptide of claim 114 and a pharmaceutically acceptable excipient.
119. (New) The pharmaceutical composition of 118, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
120. (New) An isolated polypeptide comprising an amino acid sequence at least 95% identical to
- a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
wherein said sequence comprises a K179E SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.

121. (New) The polypeptide of claim 120, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.
122. (New) The polypeptide of claim 120, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.
123. (New) The polypeptide of claim 120, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
124. (New) The polypeptide of claim 120, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
125. (New) A composition comprising the polypeptide of claim 120 and at least one excipient.
126. (New) The composition of claim 125, wherein said excipient is a pharmaceutically acceptable excipient.
127. (New) The composition of 125, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
128. (New) A pharmaceutical composition comprising the polypeptide of claim 120 and a pharmaceutically acceptable excipient.
129. (New) The pharmaceutical composition of 128, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

130. (New) An isolated polypeptide comprising:
 - a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
wherein said sequence comprises a Q102K SNP.
131. (New) A composition comprising the polypeptide of claim 130 and at least one excipient.
132. (New) The composition of claim 131, wherein said excipient is a pharmaceutically acceptable excipient.
133. (New) The composition of 131, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
134. (New) A pharmaceutical composition comprising the polypeptide of claim 130 and a pharmaceutically acceptable excipient.
135. (New) The pharmaceutical composition of 134, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
136. (New) An isolated polypeptide comprising an amino acid sequence at least 95% identical to
 - a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
wherein said sequence comprises a Q102K SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.
137. (New) The polypeptide of claim 136, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.

138. (New) The polypeptide of claim 136, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.
139. (New) The polypeptide of claim 136, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
140. (New) The polypeptide of claim 136, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
141. (New) A composition comprising the polypeptide of claim 136 and at least one excipient.
142. (New) The composition of claim 141, wherein said excipient is a pharmaceutically acceptable excipient.
143. (New) The composition of 141, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
144. (New) A pharmaceutical composition comprising the polypeptide of claim 136 and a pharmaceutically acceptable excipient.
145. (New) The pharmaceutical composition of 144, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
146. (New) An isolated polypeptide comprising:
 - a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a Q114H SNP.

147. (New) A composition comprising the polypeptide of claim 146 and at least one excipient.
148. (New) The composition of claim 147, wherein said excipient is a pharmaceutically acceptable excipient.
149. (New) The composition of 147, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
150. (New) A pharmaceutical composition comprising the polypeptide of claim 146 and a pharmaceutically acceptable excipient.
151. (New) The pharmaceutical composition of 150, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
152. (New) An isolated polypeptide comprising an amino acid sequence at least 95% identical to
 - a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a Q114H SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.
153. (New) The polypeptide of claim 152, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.
154. (New) The polypeptide of claim 152, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.
155. (New) The polypeptide of claim 152, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.

156. (New) The polypeptide of claim 152, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
157. (New) A composition comprising the polypeptide of claim 152 and at least one excipient.
158. (New) The composition of claim 157, wherein said excipient is a pharmaceutically acceptable excipient.
159. (New) The composition of 157, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
160. (New) A pharmaceutical composition comprising the polypeptide of claim 152 and a pharmaceutically acceptable excipient.
161. (New) The pharmaceutical composition of 160, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
162. (New) An isolated polypeptide comprising:
 - a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a V127D SNP.
163. (New) A composition comprising the polypeptide of claim 162 and at least one excipient.
164. (New) The composition of claim 163, wherein said excipient is a pharmaceutically acceptable excipient.

165. (New) The composition of 163, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
166. (New) A pharmaceutical composition comprising the polypeptide of claim 162 and a pharmaceutically acceptable excipient.
167. (New) The pharmaceutical composition of 166, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
168. (New) An isolated polypeptide comprising an amino acid sequence at least 95% identical to
 - a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a V127D SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.
169. (New) The polypeptide of claim 168, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.
170. (New) The polypeptide of claim 168, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.
171. (New) The polypeptide of claim 168, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
172. (New) The polypeptide of claim 168, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.

173. (New) A composition comprising the polypeptide of claim 168 and at least one excipient.
174. (New) The composition of claim 173, wherein said excipient is a pharmaceutically acceptable excipient.
175. (New) The composition of 173, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
176. (New) A pharmaceutical composition comprising the polypeptide of claim 168 and a pharmaceutically acceptable excipient.
177. (New) The pharmaceutical composition of 176, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
178. (New) An isolated polypeptide comprising:
 - a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises an A42G SNP.
179. (New) A composition comprising the polypeptide of claim 178 and at least one excipient.
180. (New) The composition of claim 179, wherein said excipient is a pharmaceutically acceptable excipient.
181. (New) The composition of 179, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
182. (New) A pharmaceutical composition comprising the polypeptide of claim 178 and a pharmaceutically acceptable excipient.

183. (New) The pharmaceutical composition of 182, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
184. (New) An isolated polypeptide comprising an amino acid sequence at least 95% identical to
 - a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises an A42G SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.
185. (New) The polypeptide of claim 184, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.
186. (New) The polypeptide of claim 184, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.
187. (New) The polypeptide of claim 184, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
188. (New) The polypeptide of claim 184, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
189. (New) A composition comprising the polypeptide of claim 184 and at least one excipient.
190. (New) The composition of claim 189, wherein said excipient is a pharmaceutically acceptable excipient.

191. (New) The composition of 189, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
192. (New) A pharmaceutical composition comprising the polypeptide of claim 184 and a pharmaceutically acceptable excipient.
193. (New) The pharmaceutical composition of 192, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.